Arshia Ehsanipour

Arshia Ehsanipour

Auto-generated profile, based on publicly available information

Arshia Ehsanipour

Department of Biomedical Engineering, University of California Davis, One Shields Ave, Davis, CA 95616 (USA)

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2018 in Cancer Research
Verified
Journal Article
Closed access
PDF file
WXWeikun Xiao
Weikun Xiao
RZRongyu Zhang
Rongyu Zhang
ASAlireza Sohrabi
Alireza Sohrabi
AEArshia Ehsanipour
Arshia Ehsanipour
SSSongping Sun
Songping Sun
SSStephanie Seidlits
Stephanie Seidlits
Glioblastoma (GBM) tumors exhibit potentially actionable genetic alterations against which targeted therapies have been effective in treatment of other cancers. However, these therapies have largely failed in GBM patients. A notable example is kinase inhibitors of EGFR, which display poor clinical efficacy despite overexpression and/or mutation of EGFR in >50% of GBM. In addressing this issue, preclinical models may be limited by the inability to accurately replicate pathophysiologic interactions of GBM cells with unique aspects of the brain extracellular matrix (ECM), which is relatively enriched in hyaluronic acid (HA) and flexible. In this study, we present a brain-mimetic biomaterial ECM platform for 3D culturing of patient-derived GBM cells, with improved pathophysiologic properties as an experimental model. Compared with orthotopic xenograft assays, the novel biomaterial cultures we developed better preserved the physiology and kinetics of acquired resistance to the EGFR inhibition than gliomasphere cultures. Orthogonal modulation of both HA content and mechanical properties of biomaterial scaffolds was required to achieve this result. Overall, our findings show how specific interactions between GBM cell receptors and scaffold components contribute significantly to resistance to the cytotoxic effects of EGFR inhibition. Significance: Three-dimensional culture scaffolds of glioblastoma provide a better physiological representation over current methods of patient-derived cell culture and xenograft models. Cancer Res; 78(5); 1358–70. ©2017 AACR.

16 June 2014 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
Dong-Sik ShinDong-Sik Shin
Dong-Sik Shin
JYJungmok You
Jungmok You
ARAli Rahimian
Ali Rahimian
TVTam Vu
Tam Vu
CSChristian Siltanen
Christian Siltanen
ARAlexander Revzin
Alexander Revzin

5 October 2016 in Cells Tissues Organs
Verified
Journal Article
Closed access
PDF file
ZKZin Z. Khaing
Zin Z. Khaing
AEArshia Ehsanipour
Arshia Ehsanipour
CHChristoph P. Hofstetter
Christoph P. Hofstetter
SSStephanie K. Seidlits
Stephanie K. Seidlits
Spinal cord injury (SCI) is a devastating condition that leaves patients with limited motor and sensory function at and below the injury site, with little to no hope of a meaningful recovery. Because of their ability to mimic multiple features of central nervous system (CNS) tissues, injectable hydrogels are being developed that can participate as therapeutic agents in reducing secondary injury and in the regeneration of spinal cord tissue. Injectable biomaterials can provide a supportive substrate for tissue regeneration, deliver therapeutic factors, and regulate local tissue physiology. Recent reports of increasing intraspinal pressure after SCI suggest that this physiological change can contribute to injury expansion, also known as secondary injury. Hydrogels contain high water content similar to native tissue, and many hydrogels absorb water and swell after formation. In the case of injectable hydrogels for the spinal cord, this process often occurs in or around the spinal cord tissue, and thus may affect intraspinal pressure. In the future, predictable swelling properties of hydrogels may be leveraged to control intraspinal pressure after injury. Here, we review the physiology of SCI, with special attention to the current clinical and experimental literature, underscoring the importance of controlling intraspinal pressure after SCI. We then discuss how hydrogel fabrication, injection, and swelling can impact intraspinal pressure in the context of developing injectable biomaterials for SCI treatment.

1 September 2016 in The American Journal of Pathology
Verified
Journal Article
Closed access
JLJina Lim
Jina Lim
AEArshia Ehsanipour
Arshia Ehsanipour
JHJeffrey J. Hsu
Jeffrey J. Hsu
JLJinxiu Lu
Jinxiu Lu
TPTaylor Pedego
Taylor Pedego
Yin TintutYin Tintut
Yin Tintut

1 March 2021 in APL Bioengineering
Verified
Journal Article
Open access
PDF file
AEArshia Ehsanipour
Arshia Ehsanipour
MSMayilone Sathialingam
Mayilone Sathialingam
LRLaila M. Rad
Laila M. Rad
JRJoseph de Rutte
Joseph de Rutte
RBRebecca D. Bierman
Rebecca D. Bierman
SSStephanie Seidlits
Stephanie Seidlits
Biomaterials are being developed as therapeutics for spinal cord injury (SCI) that can stabilize and bridge acute lesions and mediate the delivery of transgenes, providing a localized and sustained reservoir of regenerative factors. For clinical use, direct injection of biomaterial scaffolds is preferred to enable conformation to unique lesions and minimize tissue damage. While an interconnected network of cell-sized macropores is necessary for rapid host cell infiltration into—and thus integration of host tissue with—implanted scaffolds, injectable biomaterials have generally suffered from a lack of control over the macrostructure. As genetic vectors have short lifetimes in vivo, rapid host cell infiltration into scaffolds is a prerequisite for efficient biomaterial-mediated delivery of transgenes. We present scaffolds that can be injected and assembled in situ from hyaluronic acid (HA)-based, spherical microparticles to form scaffolds with a network of macropores (∼10 μm). The results demonstrate that addition of regularly sized macropores to traditional hydrogel scaffolds, which have nanopores (∼10 nm), significantly increases the expression of locally delivered transgene to the spinal cord after a thoracic injury. Maximal cell and axon infiltration into scaffolds was observed in scaffolds with more regularly sized macropores. The delivery of lentiviral vectors encoding the brain-derived neurotrophic factor (BDNF), but not neurotrophin-3, from these scaffolds further increased total numbers and myelination of infiltrating axons. Modest improvements to the hindlimb function were observed with BDNF delivery. The results demonstrate the utility of macroporous and injectable HA scaffolds as a platform for localized gene therapies after SCI.

16 June 2014 in Angewandte Chemie
Verified
Journal Article
Closed access
PDF file
Dong-Sik ShinDong-Sik Shin
Dong-Sik Shin
JYJungmok You
Jungmok You
ARAli Rahimian
Ali Rahimian
TVTam Vu
Tam Vu
CSChristian Siltanen
Christian Siltanen
ARAlexander Revzin
Alexander Revzin